LianBio (LIAN) Competitors

$0.11 +0.00 (+0.09%)

As of 05/22/2026

LIAN vs. ATYR, MGX, KALA, GOSS, and INCR

Should you buy LianBio stock or one of its competitors? MarketBeat compares LianBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LianBio include aTyr Pharma (ATYR), Metagenomi (MGX), KALA BIO (KALA), Gossamer Bio (GOSS), and InterCure (INCR). These companies are all part of the "pharmaceutical products" industry.

How does LianBio compare to aTyr Pharma?

LianBio (NASDAQ:LIAN) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

aTyr Pharma has higher revenue and earnings than LianBio. aTyr Pharma is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
aTyr Pharma	$190K	252.87	-$74.12M	-$0.73	N/A

aTyr Pharma has a consensus price target of $25.67, indicating a potential upside of 5,138.10%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

In the previous week, aTyr Pharma had 4 more articles in the media than LianBio. MarketBeat recorded 4 mentions for aTyr Pharma and 0 mentions for LianBio. aTyr Pharma's average media sentiment score of 0.50 beat LianBio's score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
LianBio	Neutral
aTyr Pharma	Positive

74.8% of LianBio shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 7.6% of LianBio shares are owned by insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

LianBio's return on equity of -33.17% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
aTyr Pharma	N/A	-100.14%	-73.55%

LianBio has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Summary

aTyr Pharma beats LianBio on 10 of the 15 factors compared between the two stocks.

How does LianBio compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Metagenomi currently has a consensus target price of $9.00, suggesting a potential upside of 566.67%. Given Metagenomi's stronger consensus rating and higher possible upside, research analysts clearly believe Metagenomi is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

74.8% of LianBio shares are held by institutional investors. 17.8% of Metagenomi shares are held by company insiders. Comparatively, 7.6% of LianBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Metagenomi's average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.

Company	Overall Sentiment
Metagenomi	Neutral
LianBio	Neutral

LianBio has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. LianBio's return on equity of -33.17% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
LianBio	N/A	-33.17%	-30.19%

Metagenomi has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, LianBio has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

Metagenomi has higher revenue and earnings than LianBio. Metagenomi is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	2.02	-$87.87M	-$2.30	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

Summary

Metagenomi beats LianBio on 8 of the 14 factors compared between the two stocks.

How does LianBio compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

KALA BIO presently has a consensus price target of $1,018.75, indicating a potential upside of 41,823.87%. Given KALA BIO's stronger consensus rating and higher possible upside, equities analysts plainly believe KALA BIO is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

LianBio's return on equity of -33.17% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
LianBio	N/A	-33.17%	-30.19%

LianBio is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

In the previous week, KALA BIO had 2 more articles in the media than LianBio. MarketBeat recorded 2 mentions for KALA BIO and 0 mentions for LianBio. KALA BIO's average media sentiment score of 0.21 beat LianBio's score of 0.00 indicating that KALA BIO is being referred to more favorably in the media.

Company	Overall Sentiment
KALA BIO	Neutral
LianBio	Neutral

KALA BIO has a beta of -2.23, indicating that its stock price is 323% less volatile than the broader market. Comparatively, LianBio has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

24.6% of KALA BIO shares are held by institutional investors. Comparatively, 74.8% of LianBio shares are held by institutional investors. 2.2% of KALA BIO shares are held by company insiders. Comparatively, 7.6% of LianBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

KALA BIO beats LianBio on 7 of the 13 factors compared between the two stocks.

How does LianBio compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Gossamer Bio had 21 more articles in the media than LianBio. MarketBeat recorded 21 mentions for Gossamer Bio and 0 mentions for LianBio. Gossamer Bio's average media sentiment score of 0.06 beat LianBio's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Gossamer Bio	Neutral
LianBio	Neutral

LianBio has lower revenue, but higher earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	1.02	-$170.37M	-$0.79	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

Gossamer Bio has a beta of 2.15, meaning that its stock price is 115% more volatile than the broader market. Comparatively, LianBio has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 74.8% of LianBio shares are held by institutional investors. 7.2% of Gossamer Bio shares are held by insiders. Comparatively, 7.6% of LianBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

LianBio has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
LianBio	N/A	-33.17%	-30.19%

Gossamer Bio presently has a consensus price target of $5.00, suggesting a potential upside of 2,279.82%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Gossamer Bio beats LianBio on 10 of the 15 factors compared between the two stocks.

How does LianBio compare to InterCure?

LianBio (NASDAQ:LIAN) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

InterCure has higher revenue and earnings than LianBio. LianBio is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
InterCure	$78.47M	0.61	-$10.37M	$0.03	29.30

74.8% of LianBio shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 7.6% of LianBio shares are owned by company insiders. Comparatively, 0.2% of InterCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, InterCure has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

InterCure's return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
InterCure	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, LianBio's average media sentiment score of 0.00 equaled InterCure'saverage media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
InterCure	Neutral

Summary

InterCure beats LianBio on 8 of the 10 factors compared between the two stocks.

Get LianBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIAN vs. The Competition

Export

Metric	LianBio	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.91M	$470.48M	$6.46B	$12.34B
Dividend Yield	N/A	3.87%	2.76%	5.28%
P/E Ratio	-0.14	3.86	21.22	25.66
Price / Sales	N/A	7,482.36	562.28	86.31
Price / Cash	N/A	13.13	43.49	56.67
Price / Book	0.04	84.13	10.31	7.14
Net Income	-$110.29M	-$96.07M	$3.57B	$335.98M
7 Day Performance	0.09%	0.16%	6.43%	4.15%
1 Month Performance	-9.67%	0.72%	3.57%	2.54%
1 Year Performance	-69.39%	63.70%	34.07%	35.06%

LianBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIAN LianBio	N/A	$0.11 +0.1%	N/A	-69.4%	$11.91M	N/A	N/A	110
ATYR aTyr Pharma	2.231 of 5 stars	$0.53 +9.9%	$25.67 +4,737.3%	-86.9%	$47.36M	$190K	N/A	53	Gap Up
MGX Metagenomi	2.4423 of 5 stars	$1.29 +3.2%	$9.00 +597.7%	-16.7%	$47.06M	$25.21M	N/A	236
KALA KALA BIO	2.0797 of 5 stars	$2.65 +4.7%	$1,018.75 +38,343.4%	-98.8%	$47.03M	N/A	N/A	30	Analyst Upgrade Gap Up
GOSS Gossamer Bio	2.7904 of 5 stars	$0.22 +8.1%	$5.00 +2,222.3%	-82.5%	$46.73M	$48.47M	N/A	180	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIAN) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LianBio (LIAN) Competitors